Viking Therapeutics (VKTX) Research & Development (2014 - 2026)

Viking Therapeutics has disclosed Research & Development across 13 years of filings, most recently posting $150.2 million for Q1 2026.

• Research & Development for Q1 2026 came in at $150.2 million, up 262.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $453.7 million (up 281.49% YoY), and the FY2025 annual result was $345.0 million, up 239.38% from the prior year.
• Research & Development came in at $150.2 million for Q1 2026 at Viking Therapeutics, down from $153.5 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $153.5 million in Q4 2025 to a low of $11.0 million in Q1 2023.
• The 5-year median for Research & Development is $22.8 million (2024), against an average of $42.0 million.
• Across the five-year window, Research & Development slipped 12.32% in 2023 and jumped 395.24% in 2025, its largest moves.
• Viking Therapeutics' Research & Development stood at $16.2 million in 2022, then grew by 26.73% to $20.5 million in 2023, then soared by 51.14% to $31.0 million in 2024, then surged by 395.24% to $153.5 million in 2025, then fell by 2.16% to $150.2 million in 2026.
• The last three Research & Development figures came in at $150.2 million (Q1 2026), $153.5 million (Q4 2025), and $90.0 million (Q3 2025), per Business Quant data.